Cochrane confirms: nicotine vapes beat patches for quitting

What just happened

An updated Cochrane systematic review — summarised by Emeritus Professor Wayne Hall of the University of Queensland — finds that nicotine-containing e-cigarettes are more effective at helping people quit smoking than nicotine patches, gums, or behavioural support alone.

The headline numbers: approximately 8–10 people per 100 successfully stop smoking using nicotine vapes. The comparable figure for traditional nicotine replacement therapy — patches, gums, lozenges — is 6 per 100. Against non-nicotine vapes, nicotine vapes produce roughly 2 additional quitters per 100. Against behavioural support alone, the gap is approximately 5 more quitters per 100.

These absolute differences are modest. In the context of smoking cessation — where success rates across all modalities are persistently low, and where each additional quitter represents substantial averted harm — the difference between 6% and 10% is clinically meaningful.

The review drew on 80 randomised controlled trials involving nearly 30,000 participants. Critically, findings held when studies with high bias risk or tobacco industry funding were excluded.

---

The both-and

The evidence is robust

Cochrane reviews represent the highest tier of systematic evidence synthesis. This is not a single trial or a result from a subset of interested researchers — it is 80 trials, nearly 30,000 participants, with a conclusion stable across multiple sensitivity analyses.

The mechanism is plausible. Nicotine e-cigarettes replicate the behavioural ritual of smoking — hand-to-mouth movement, inhalation, visible exhalation — alongside nicotine delivery. For a behaviour as entrenched as cigarette smoking, that ritual component may partly explain why patches, which deliver nicotine without the behaviour, work less well. The finding that nicotine vapes outperform non-nicotine vapes by approximately 2 per 100 confirms that nicotine delivery itself, not just behavioural substitution, contributes to the effect.

In clinical terms: if a patient has tried nicotine patches, gums, and lozenges without success and is still smoking, there is now high-quality evidence that nicotine vapes may work where NRT did not.

The Australian landscape is tangled

Here is where the evidence meets a complicated reality specific to Australia.

The TGA has not approved nicotine-containing e-cigarettes for general over-the-counter use. Since October 2024, a special access scheme allows pharmacists to dispense certain nicotine-containing vapes without a prescription — a meaningful regulatory liberalisation. But the evidence in this review applies to clinical trial participants using research-grade products under study conditions, not to the consumer products circulating in the Australian market.

The most striking figure in the Australian context: 93% of Australians who use nicotine vapes still purchase them from illegal sources, despite the pharmacist-dispensing scheme existing. The legal pathway is there; it is not being used at scale.

This creates a clinical gap. A GP cannot readily point a patient to a well-regulated, clearly characterised product. The pharmacist-dispensed range is limited. Products from tobacconists, convenience stores, and online grey-market suppliers — which is what most patients are actually using — exist outside any quality, safety, or content assurance framework. The Cochrane evidence tells you that nicotine vapes work as a category; it does not tell you that the specific product your patient is using is safe or contains what the label says.

The review also carries methodological caveats worth knowing. Most studies followed participants for only six months, leaving long-term relapse rates — which would be the more clinically meaningful outcome — largely uncharacterised. Many studies used older vape technology with less efficient nicotine delivery than current consumer products. Whether modern, high-concentration-nicotine devices produce better or worse outcomes than those study devices is unknown.

And the review did not assess the health consequences of long-term vaping alone. The working assumption in the harm-reduction literature — that switching fully from cigarettes to vaping reduces overall harm — is well-supported for combustion-related carcinogens. The respiratory, cardiovascular, and oncological profile of sustained vaping over years to decades is less completely characterised.

The population reality

Smoking rates in Australia have fallen substantially over the past three decades, primarily through tobacco excise, plain packaging, and public health campaigns. The remaining smokers are, on average, more dependent and more marginalised than the cohort who quit earlier. Many have tried patches and gums repeatedly without success. For this group, the Cochrane finding is clinically significant.

At the same time, vaping is driving a parallel trend: adolescent uptake of nicotine through vaping among people who never smoked. The clinical and public health calculus for a 45-year-old long-term smoker trying to quit is genuinely different from the calculus for a 17-year-old initiating nicotine use through a vape device. The Cochrane review addresses the former; it does not address the latter.

---

My two cents

For a patient who smokes, has tried NRT multiple times, and is asking about vapes as a quit tool — the Cochrane data is clinically relevant and should be part of the conversation.

In Australian general practice, the practical path is to:

• Check whether access to a pharmacist-dispensed product under the TGA scheme is realistic for this patient
• Frame the goal as cessation from both cigarettes and vaping, not indefinite substitution
• Combine any vaping-based quit attempt with behavioural support
• Review at three months, and if the patient is still vaping at six months without having quit cigarettes, address the ongoing nicotine dependence directly

What the evidence does not support is treating nicotine vapes as a neutral lifestyle product, or advising patients that they can vape indefinitely once they have stopped cigarettes. The cessation trajectory is the point.

For patients already using illegally purchased vapes, the immediate harm-reduction framing — vaping instead of cigarettes reduces combustion-related risk — may apply, alongside a plan to work toward cessation from both.

Verdict: maybe — the Cochrane evidence is stronger than NRT, but the Australian regulatory reality and the unknowns around long-term vaping safety make this a clinical conversation that needs individual tailoring, not a simple recommendation.

---

Sources cited

1. “Vaping is better than patches or gums for quitting smoking — updated review” — The Conversation, August 2026. https://theconversation.com/vaping-is-better-than-patches-or-gums-for-quitting-smoking-updated-review-290420